Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchZincZinc (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
Analgesics⏵
Antiandrogens⏵
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Supplementary Data — Zinc for COVID-19: real-time meta analysis of 61 studies (44 treatment studies and 17 sufficiency studies)

@CovidAnalysis, April 2024, Version 62V62
Post
Share
PDF
Studies
Feedback
https://c19early.org/zmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Derwand 79% 0.21 [0.03-1.47] death 1/141 13/377 CT​2​ Improvement, RR [CI] Treatment Control Derwand 82% 0.18 [0.07-0.54] hosp. 4/141 58/377 CT​2​ COVIDAtoZ Thomas (RCT) -44% 1.44 [0.36-5.71] hosp. 5/58 3/50 COVIDAtoZ Thomas (RCT) 12% 0.88 [0.67-1.16] recov. time 58 (n) 50 (n) Aldwihi 24% 0.76 [0.51-1.08] hosp. 53/199 184/539 Asimi 97% 0.03 [0.00-0.44] ventilation 0/270 9/86 CT​2​ Asimi 99% 0.01 [0.00-0.16] hosp. 0/270 24/86 CT​2​ Asimi 100% 0.00 [0.00-0.08] severe case 0/270 51/86 CT​2​ Mayberry 53% 0.47 [0.33-0.65] death 938 (n) 1,090 (n) Mayberry 64% 0.36 [0.27-0.47] ventilation 938 (n) 1,090 (n) Mayberry 60% 0.40 [0.31-0.52] ICU 938 (n) 1,090 (n) Mayberry 58% 0.42 [0.33-0.54] death/v/ICU 938 (n) 1,090 (n) Mayberry 85% 0.15 [0.10-0.22] progression 938 (n) 1,090 (n) VIZIR Abdallah (DB RCT) 30% 0.70 [0.36-1.31] death 15/231 22/239 VIZIR Abdallah (DB RCT) 38% 0.62 [0.37-0.99] death/ICU 24/231 40/239 VIZIR Abdallah (DB RCT) 54% 0.46 [0.23-0.88] ICU 12/231 27/239 VIZIR Abdallah (DB RCT) 42% 0.58 [0.39-0.87] oxygen 31/231 55/239 VIZIR Abdallah (DB RCT) 23% 0.77 [0.65-0.91] oxygen 108/231 145/239 VIZIR Abdallah (DB RCT) 29% 0.71 [0.57-0.88] no recov. 82/231 120/239 VIZIR Abdallah (DB RCT) 14% 0.86 [0.80-0.93] no recov. 180/231 216/239 VIZIR Abdallah (DB RCT) 69% 0.31 [0.03-2.61] hosp. 1/85 4/100 VIZIR Abdallah (DB RCT) 33% 0.67 [0.59-0.75] hosp. time 146 (n) 134 (n) VIZIR Abdallah (DB RCT) 25% 0.75 [0.65-0.87] recov. time 85 (n) 100 (n) Carlucci 38% 0.62 [0.46-0.84] death/HPC 54/411 119/521 Carlucci 18% 0.82 [0.54-1.25] ventilation 29/411 62/521 Carlucci 23% 0.77 [0.53-1.10] ICU 38/411 82/521 Krishnan 18% 0.82 [0.62-1.09] death 31/58 61/94 Yao 34% 0.66 [0.41-1.07] death 73/196 21/46 Frontera (PSM) 37% 0.63 [0.44-0.91] death 121/1,006 424/2,467 CT​2​ Frontera (PSM) 24% 0.76 [0.60-0.96] death 121/1,006 424/2,467 CT​2​ Abd-Elsalam (RCT) 1% 0.99 [0.30-3.31] death 5/96 5/95 data issues, see notes Abd-Elsalam (RCT) 34% 0.66 [0.19-2.26] ventilation 4/96 6/95 data issues, see notes Abd-Elsalam (RCT) 6% 0.94 [0.55-1.62] no recov. 20/96 21/95 data issues, see notes Abd-Elsalam (RCT) 4% 0.96 [0.86-1.08] hosp. time 96 (n) 95 (n) data issues, see notes Rosenthal -16% 1.16 [1.05-1.28] death n/a n/a Darban (RCT) 33% 0.67 [0.14-3.17] progression 2/10 3/10 ICU patients CT​2​ Darban (RCT) 6% 0.94 [0.84-1.06] ICU 10 (n) 10 (n) ICU patients CT​2​ Patel (DB RCT) 20% 0.80 [0.15-4.18] death 2/15 3/18 Mulhem 46% 0.54 [0.43-0.68] death 256/1,596 260/1,623 Gadhiya -41% 1.41 [0.69-2.57] death 21/54 34/229 Al Sulaiman (ICU) 36% 0.64 [0.37-1.10] death 23/82 32/82 ICU patients Al Sulaiman (ICU) 48% 0.52 [0.29-0.92] death 19/82 31/82 ICU patients Al Sulaiman (ICU) -25% 1.25 [0.84-1.87] ICU 82 (n) 82 (n) ICU patients Al Sulaiman (ICU) -6% 1.06 [0.85-1.33] hosp. time 82 (n) 82 (n) ICU patients Elavarasi 65% 0.35 [0.24-0.56] death 486 (n) 1,201 (n) Assiri (ICU) -81% 1.81 [0.41-6.97] death 10/60 4/58 ICU patients Reszinate Kaplan (RCT) -14% 1.14 [0.08-16.6] ventilation 1/14 1/16 CT​2​ Reszinate Kaplan (RCT) -14% 1.14 [0.08-16.6] ICU 1/14 1/16 CT​2​ Reszinate Kaplan (RCT) -14% 1.14 [0.08-16.6] hosp. 1/14 1/16 CT​2​ Zangeneh (ICU) -21% 1.21 [0.51-2.90] death n/a n/a ICU patients Alahmari 30% 0.70 [0.63-0.78] hosp. time 130 (n) 847 (n) Doocy 41% 0.59 [0.19-1.85] death 3/28 21/116 Ibrahim Alhajjaji 88% 0.12 [0.01-2.24] death 0/44 4/57 Ibrahim Alhajjaji 26% 0.74 [0.23-2.37] ventilation 4/44 7/57 Ibrahim Alhajjaji 3% 0.97 [0.45-2.10] ICU 9/44 12/57 Ibrahim Alhajjaji 73% 0.27 [0.10-0.74] progression 4/44 19/57 Ibrahim Alhajjaji 29% 0.71 [0.54-0.94] hosp. time 44 (n) 57 (n) Kyagambiddwa 25% 0.75 [0.44-1.25] death 20/89 22/73 Seely (DB RCT) 48% 0.52 [0.10-2.71] progression 2/42 4/44 CT​2​ Seely (DB RCT) 14% 0.86 [0.61-1.22] no recov. 34 (n) 24 (n) CT​2​ Seely (DB RCT) 29% 0.71 [0.28-1.75] no recov. 7/34 7/24 CT​2​ Seely (DB RCT) 29% 0.71 [0.31-1.65] no recov. 32 (n) 31 (n) CT​2​ Seely (DB RCT) 14% 0.86 [0.37-1.97] no recov. 33 (n) 30 (n) CT​2​ Seely (DB RCT) 50% 0.50 [0.19-1.34] no recov. 32 (n) 33 (n) CT​2​ Seely (DB RCT) -12% 1.12 [0.82-1.54] no recov. 30 (n) 25 (n) CT​2​ Seely (DB RCT) -4% 1.04 [0.77-1.40] recov. time 34 (n) 24 (n) CT​2​ Seely (DB RCT) 12% 0.88 [0.19-4.02] PASC 3/33 3/29 CT​2​ Seely (DB RCT) 36% 0.64 [0.16-2.65] PASC 3/35 4/30 CT​2​ Seely (DB RCT) 1% 0.99 [0.34-2.93] PASC 6/35 5/29 CT​2​ Louca 1% 0.99 [0.93-1.06] cases population-based cohort Mahto 37% 0.63 [0.22-1.49] IgG+ 10/38 83/651 Bejan 18% 0.82 [0.22-3.13] ventilation 155 (n) 9,074 (n) Bejan 30% 0.70 [0.19-2.54] ICU 155 (n) 9,112 (n) COVIDENCE UK Holt 7% 0.93 [0.59-1.44] cases 21/750 425/14,477 Abdulateef 13% 0.87 [0.38-1.97] hosp. 7/111 23/317 Seet (CLUS. RCT) 50% 0.50 [0.34-0.75] symp. case 33/634 64/619 OT​1​ Seet (CLUS. RCT) 27% 0.73 [0.55-0.97] cases 300/634 433/619 OT​1​ Israel 100% 0.00 [0.00-0.89] hosp. case control CT​2​ Bagheri 60% 0.40 [0.04-3.53] severe case 33 (n) 477 (n) Bagheri 41% 0.59 [0.14-1.61] hosp. 4/33 167/477 Gordon 68% 0.32 [0.01-7.87] death 0/104 1/96 Gordon 85% 0.15 [0.02-0.58] symp. case 2/104 9/96 Kumar 20% 0.80 [0.21-2.99] death 6/75 3/30 Nimer -25% 1.25 [0.87-1.77] hosp. 41/326 178/1,822 Nimer -13% 1.13 [0.81-1.56] severe case 46/326 214/1,822 Shehab 47% 0.53 [0.19-1.47] severe case 4/65 22/188 Citu 18% 0.82 [0.12-5.68] severe case 2/74 2/61 CT​2​ Stambouli (DB RCT) 68% 0.32 [0.03-2.95] symp. case 1/59 3/56 Stambouli (DB RCT) 5% 0.95 [0.29-3.10] cases 5/59 5/56 Stambouli (DB RCT) 21% 0.79 [0.73-0.84] viral load 59 (n) 56 (n) Adrean -12% 1.12 [0.74-1.70] cases 30/2,111 80/6,315 Sharif 40% 0.60 [0.46-0.77] severe case n/a n/a Sharif 97% 0.03 [0.01-0.22] severe case n/a n/a Asoudeh 57% 0.43 [0.21-0.90] severe case 250 (all patients) Seifi 31% 0.69 [0.52-0.94] hosp. n/a n/a per unit change Zinc COVID-19 outcomes c19early.org April 2024 ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors zinc Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0